Bridge to Life Secures $110 Million to Revolutionize Organ Preservation in Transplantation

In a significant move towards modernizing liver transplantation and enhancing organ preservation strategies, Bridge to Life™ Ltd. has announced the successful completion of a $110 million Series C and debt financing. This funding round, led by Soleus Capital with participation from Lauxera Capital Partners, marks a significant milestone for the company, recognized as a leader in organ preservation solutions and perfusion technologies. The investment comes at a crucial time as the company prepares to expand its state-of-the-art VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, the first FDA-cleared system of its kind for liver transplantation.

Financial Strategy and Growth Outlook

The newly acquired capital will primarily be utilized to accelerate the early commercial rollout of the VitaSmart™ HOPE System across the United States. This investment will allow Bridge to Life to extend its field team and secure working capital essential for reaching every U.S. transplant center effectively. Additionally, part of the funds will focus on advancing a new viability assessment tool—aiming to set a new standard in organ viability assessment, which will enable transplant centers to maximize organ usage and ultimately save more lives.

CEO Don Webber emphasized the company’s commitment to enhancing transplant medicine with science-backed solutions that increase organ availability. "This financing reflects the confidence our investors have in our technology, team, and long-term growth strategy," stated Webber. He also noted that the demand for VitaSmart™ is already exceeding expectations, with leading academic centers rapidly adopting the technology.

Meeting the Critical Need for Organ Viability

Currently, over 100,000 patients in the U.S. are awaiting potentially life-saving organ transplants, heightening the necessity for optimizing the utilization of available donor organs. The VitaSmart™ System specifically addresses this dire need by broadening the pool of viable organs, which helps to mitigate patient wait times significantly.

The innovative viability assessment tool being developed by Bridge to Life aims to enhance decision-making in organ acceptance. This tool will provide objective assessments that surgeons can rely on to accept marginal or extended-criteria grafts, a common challenge in organ transplantation. By augmenting traditional evaluation methods with a more definitive scientific approach, the company looks to set a new industry-wide standard in transplant medicine.

Expansion Beyond Liver Transplantation

In addition to focusing on liver transplants, Bridge to Life plans to use part of the funding to expand its organ preservation and perfusion portfolio beyond liver applications. This diversification strategy is designed to include additional organ types, which would further enhance the company’s global commercial footprint and address the needs of a broader patient demographic over the next several years.

Moreover, Bridge to Life is actively working on next-generation closed systems that facilitate safer transport of organs, thereby streamlining processes in organ transplantation.

Future Prospects and Industry Impact

As a company that prioritizes innovation, Bridge to Life not only aims to maintain strong customer relationships—demonstrated by an increasing trend of repeat orders—but also seeks to forge master service agreements with numerous transplant centers and organ procurement organizations across the nation. This collaborative ethos positions the company to meet the rigorous demands of modern transplant medicine while nurturing lasting relationships within the healthcare ecosystem.

With the backing of Soleus Capital and Lauxera Capital Partners, Bridge to Life is well-equipped to achieve its vision of revolutionizing organ transplantation and improving patient outcomes with cutting-edge solutions.

Conclusion

In summary, the recent financing efforts signal a new phase for Bridge to Life as it endeavors to redefine organ preservation practices. Their strategic focus on expanding the VitaSmart™ system and pioneering viability assessment technologies not only places them at the forefront of transplant innovation but also emphasizes their commitment to saving lives through enhanced medical technology.